Table 1.
Summary and descriptive statistics of prostate cancer patients on LHRH agonists in Ontario (n=165)
| Clinical variables | Radical prostatectomy (n=61) | Radiation (n=52) | Primary hormone therapy (n=52) |
|---|---|---|---|
| Age | |||
| Median | 72 | 77 | 78.6 |
| IQR | 66–79 | 73–81 | 70–85 |
| PSA (ug/L) at time of testosterone | |||
| Median | 0.21 | 0.82 | 1.55 |
| IQR | 0–3.49 | 0–7.38 | 0–9.87 |
| Serum testosterone (nmol/L) | |||
| Median | 1.4 | 1.3 | 1.25 |
| IQR | 1–1.9 | 1–1.625 | 0.9–1.525 |
| Time on LHRH (months) | |||
| Median | 60 | 60 | 66 |
| IQR | 36–108 | 25.75–108 | 24–108 |
| Disease status* | |||
| 1. Biochemical recurrence | 42.623 | 30.7692 | 1.9231 |
| 2. Metastases | 27.8689 | 25 | 44.2308 |
| 3. CRPC | 4.918 | 9.6154 | 5.7692 |
| 4. Locally advanced | 16.3934 | 32.6923 | 40.3846 |
| 5. Not known | 8.1967 | 1.9231 | 7.6923 |
PSA: prostate-specific antigen; IQR: interquartile range; LHRH: luteinizing hormone releasing-hormone; CRPC: castrate-resistant prostate cancer.
*
Values are percentages of total in each group.